Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus/sirolimus-based graft-versus-host disease prophylaxis
about
A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injuryTransplant-associated thrombotic microangiopathy: opening Pandora's box.Antineoplastic agents and thrombotic microangiopathy.Low incidence of severe cGvHD and late NRM in a phase II trial of thymoglobulin, tacrolimus and sirolimus for GvHD prevention.Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus.The potential role of HLA-DRB1*11 in the development and outcome of haematopoietic stem cell transplantation-associated thrombotic microangiopathy.Transplantation-Associated Thrombotic Microangiopathy in Patients Treated With Sirolimus and Cyclosporine as Salvage Therapy for Graft-Versus-Host Disease.Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy.Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation.Post-bone marrow transplant thrombotic microangiopathy.New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy.Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT.Mycophenolate mofetil-based salvage as acute GVHD prophylaxis after early discontinuation of tacrolimus and/or sirolimus.Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant.Graft-versus-host disease prophylaxis after transplantation: a network meta-analysis.Influence of Absorption, Distribution, Metabolism, and Excretion Genomic Variants on Tacrolimus/Sirolimus Blood Levels and Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II.Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: considerations for evidence-based GVHD prophylaxis.The efficacy and safety of sirolimus-based graft-versus-host disease prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation: a meta-analysis of randomized controlled trials.Management of drug interaction between posaconazole and sirolimus in patients who undergo hematopoietic stem cell transplant.Pre-transplant sirolimus might improve the outcome of haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide for patients with severe aplastic anemia.Risk and prognostic factors of transplantation-associated thrombotic microangiopathy in allogeneic haematopoietic stem cell transplantation: a nested case control study.Transplant-associated thrombotic microangiopathy: an unresolved complication of unrelated allogeneic transplant for hematologic diseases.
P2860
Q26992169-95E78BB4-AA76-4C45-B22C-87430D22E5EDQ30235311-079B4811-6A87-4969-BFFA-3A1454CFCD77Q30251919-FF5151B9-7588-45BD-9708-64ECDCDDB158Q30252205-8ECB561B-42DD-44D8-88AB-C6C32E6481DBQ33413498-8A2F35C1-D631-4898-BACB-BA5BDD7BE71AQ33424153-8036F6C6-AB4D-40D9-BEEA-82BE016BB166Q33424311-3535C47C-FD01-4082-9ADF-48D6295F3631Q33424902-377B1A58-D610-42A1-88D0-DE2DD224EE62Q33426602-8BBFFC76-3759-491F-BE4F-DAC08B5C81B3Q33430697-01EBA865-FA6C-4A82-B748-A51F9B51B613Q33432069-96579094-AC26-40A5-B884-438B84CD2A39Q34077792-F6E1ED5A-E904-4BC0-8FF1-FF661B146228Q35054593-56C1CFC2-ED8E-4C68-8D6F-7AF8F2EAD224Q35231363-746753B8-4116-415C-A7BF-9992AD710646Q35499395-91D9A03B-1F58-4915-9A5E-34D233E44705Q36474050-B8744BFA-4620-4392-AB1C-6CA0BCE40CA5Q36777485-D1D0C756-E663-463B-B1EB-F1E9DDF3AF25Q38202155-F4A08777-FFB5-4107-B2BD-C34E53A86EF8Q38413246-184737B1-A8B9-4805-B23F-2647B484FBC1Q40875485-29141109-4F65-479C-B26A-2DF9DD4F2D65Q45066872-06D0B7B5-6115-4EAA-A6EB-DC4EEE21919BQ53091032-1B42AF61-845E-4897-B7CB-D4D994896ED8Q54306708-9842EB7B-E456-480E-85B7-F208438741C6
P2860
Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus/sirolimus-based graft-versus-host disease prophylaxis
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Thrombotic microangiopathy ass ...... ersus-host disease prophylaxis
@ast
Thrombotic microangiopathy ass ...... ersus-host disease prophylaxis
@en
type
label
Thrombotic microangiopathy ass ...... ersus-host disease prophylaxis
@ast
Thrombotic microangiopathy ass ...... ersus-host disease prophylaxis
@en
prefLabel
Thrombotic microangiopathy ass ...... ersus-host disease prophylaxis
@ast
Thrombotic microangiopathy ass ...... ersus-host disease prophylaxis
@en
P2093
P2860
P1476
Thrombotic microangiopathy ass ...... ersus-host disease prophylaxis
@en
P2093
Joycelynne Palmer
Pablo M Parker
Ryotaro Nakamura
Samer K Khaled
Sandra H Thomas
Sepideh Shayani
Stephen J Forman
Tracey Stiller
P2860
P304
P356
10.1016/J.BBMT.2012.10.006
P577
2012-10-15T00:00:00Z